Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer

Author:

Brasky Theodore M.1ORCID,Newton Alison M.1ORCID,Conroy Sara2ORCID,Adib Anita3ORCID,Adley Neema C.4ORCID,Strassels Scott A.5ORCID,Hays John L.1ORCID,Cooper Ziva D.678ORCID,Wagener Theodore L.1ORCID,Stevens Erin9ORCID,Plascak Jesse J.3ORCID,Krok-Schoen Jessica L.10ORCID

Affiliation:

1. 1Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio.

2. 2Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio.

3. 3Division of Cancer Prevention and Control, The Ohio State University College of Medicine, Columbus, Ohio.

4. 4Department of Neuroscience, The Ohio State University College of Arts and Sciences, Columbus, Ohio.

5. 5Atrium Health, Charlotte, North Carolina.

6. 6UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California.

7. 7Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California.

8. 8Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, California.

9. 9Department of Internal Medicine, The Ohio State University College of Medicine; Columbus, Ohio.

10. 10School of Health and Rehabilitation Sciences, The Ohio State University College of Medicine, Columbus, Ohio.

Abstract

Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance:Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.

Funder

HHS | NIH | National Center for Advancing Translational Sciences

Publisher

American Association for Cancer Research (AACR)

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3